Valuation
- Market cap
- 938,363,000
- Revenue TTM
- $38,467,000
- Net income TTM
- $-932,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -2.42%
- Debt to equity
- 0.00
Trading
- Volume
- 681,900
- Avg volume
- —
- Day's range
- $21.10 – $22.73
- Shares out
- 41,631,000
- Stochastic %K
- 25%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $50.50
Company profile
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 500 8880
- Website
- https://apnimed.com
- Address
- 39 John F. Kennedy Street, 4th Floor, Cambridge, United States
Latest news
No headlines yet.
